China

Showing 1–16 of 18 results

Announcement on Approval of Active Pharmaceutical Ingredients (API), Pharmaceutical Excipients and Pharmaceutical Packaging Materials for Drug Products No.146, November 30, 2017
$100.00 Add to cart
China NMPA (Order No. 28): Administrative Measures for Drugs Registration
$350.00 Add to cart
China NMPA Order No.4: Administrative Measures for Drugs Importation
$350.00 Add to cart
China’s NMPA Decree No. 1 – Annex 3: Guideline on Medical Device Adverse Event Monitoring Scope (Draft)
$200.00 Add to cart
China’s NMPA Decree No. 1 – Annex 7: Guideline on Focus Points when Monitoring Medical Device Adverse Events (Draft)
$150.00 Add to cart
China’s NMPA Decree No. 131: Announcement on Using Chinese Name for Registrant or File Submitter of Imported Medical Devices
$100.00 Add to cart
China’s NMPA Decree No. 6: Guideline on the Design of Clinical Trials for Medical Devices
$150.00 Add to cart
China’s NMPA Decree No. 6: Regulation on Instructions for Use and Labels of Medical Devices
$200.00 Add to cart
China’s NMPA DECREE NO. 7 : Measures for Supervision and Administration of Medical Device Production
$50.00 Add to cart
China’s NMPA Decree No. 83: Innovative Medical Device Special Approval Procedure
$200.00 Add to cart
China’s NMPA Guideline No. 101: Registration of Rare Disease Control Medical Devices
$100.00 Add to cart
China’s NMPA Order No. 56 of 2019: Improving Related Issues Concerning Drug Evaluation, Approval and Supervision (DMF for API, Pharmaceutical Packaging Materials and Excipient
$100.00 Add to cart
China’s NMPA Order No.82, 2020: the Issuance of Working Procedures for Review of Breakthrough Therapies
$200.00 Add to cart
China’s NMPA” Guideline for Technical Review of Medical Device Software Registration
$200.00 Add to cart
China’s NMPA: Announcement on Record Filling of Medical Device Master Files
$50.00 Add to cart
China’s NMPA: Guideline for Clinical Trials of In Vitro Diagnostic Reagents (Draft)
$150.00 Add to cart

North America

Latin AMerica

Europe

Australia

Asia

Announcement on Approval of Active Pharmaceutical Ingredients (API), Pharmaceutical Excipients and Pharmaceutical Packaging Materials for Drug Products No.146, November 30, 2017

China NMPA (Order No. 28): Administrative Measures for Drugs Registration

China NMPA Order No.4: Administrative Measures for Drugs Importation

China’s NMPA Decree No. 1 – Annex 3: Guideline on Medical Device Adverse Event Monitoring Scope (Draft)

China’s NMPA Decree No. 1 – Annex 7: Guideline on Focus Points when Monitoring Medical Device Adverse Events (Draft)

China’s NMPA Decree No. 131: Announcement on Using Chinese Name for Registrant or File Submitter of Imported Medical Devices

China’s NMPA Decree No. 6: Guideline on the Design of Clinical Trials for Medical Devices

China’s NMPA Decree No. 6: Regulation on Instructions for Use and Labels of Medical Devices

China’s NMPA DECREE NO. 7 : Measures for Supervision and Administration of Medical Device Production

China’s NMPA Decree No. 83: Innovative Medical Device Special Approval Procedure

China’s NMPA Guideline No. 101: Registration of Rare Disease Control Medical Devices

China’s NMPA Order No. 56 of 2019: Improving Related Issues Concerning Drug Evaluation, Approval and Supervision (DMF for API, Pharmaceutical Packaging Materials and Excipient

China’s NMPA Order No.82, 2020: the Issuance of Working Procedures for Review of Breakthrough Therapies

China’s NMPA” Guideline for Technical Review of Medical Device Software Registration

China’s NMPA: Announcement on Record Filling of Medical Device Master Files

China’s NMPA: Guideline for Clinical Trials of In Vitro Diagnostic Reagents (Draft)

ABOUT GRP GROUP

GRP Headquarters

Tel : (+1 ) 781 - 672 -4200

Follow GRP on Social Media

GRP Group Offices

USEFUL LINKS